2-(2-bromopyridin-4-ylmethylthio)-N-(3,5-dimethylphenyl)pyridine-3-carboxamide | 754221-41-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-bromopyridin-4-ylmethylthio)-N-(3,5-dimethylphenyl)pyridine-3-carboxamide
• 英文别名: 2-[(2-bromopyridin-4-yl)methylsulfanyl]-N-(3,5-dimethylphenyl)pyridine-3-carboxamide
• CAS: 754221-41-5
• 化学式: C₂₀H₁₈BrN₃OS
• 分子量: 428.352
• InChiKey: ZWDACUQGQZCUOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  80.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-bromopyridin-4-ylmethylthio)-N-(3,5-dimethylphenyl)pyridine-3-carboxamide 、 N-甲基脲 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 以22%的产率得到N-(3,5-dimethylphenyl)-2-[2-(N'-methylureido)pyridin-4-ylmethylthio]pyridine-3-carboxamide
  参考文献：
  名称：

  Pyridylmethylthio derivatives as VEGF inhibitors: Part 2

  摘要：

  Optimization of compounds 5 and 6 led to the discovery of VEGF inhibitor 10g which reduced CYP inhibition. It was highly active in vitro (VEGF induced HUVEC proliferation assay) and showed efficacies in three disease models in vivo (cancer, RA, and AMD). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.071

文献信息

• Novel compounds having 4-pyridylalkylthio group as substituent
  申请人：Honda Takahiro

  公开号：US20060194836A1

  公开（公告）日：2006-08-31

  A subject of the present invention is to provide a novel aromatic five- or six-memberd heterocyclic derivative having 4-pyridylalkylthio as a substituent or a salt thereof which is useful as a pharmaceutical. Compound represented by the following general formula [I] or salts thereof are useful as therapeutic agents for diseases in which angiogenesis or augmentation of vascular permeability is involved. In the formula, ring “A” is a benzene ring or an aromatic five- or six-memberd heterocycle which can be fused with a cycloalkane ring, “B” is alkylene, R 1 and R 2 , the same or different, are H, OH, substituted or unsubstituted alkoxy and the like, X and Y, the same or different, are group(s) selected from H, halogen, OH, substituted or unsubstituted alkoxy and the like respectively, p is 0, 1 or 2, and q is 0 or 1.

  本发明的目的是提供一种新的芳香性五元或六元杂环衍生物，其具有4-吡啶基烷硫基取代基或其盐，可作为药物使用。以下通式[I]所表示的化合物或其盐可用作治疗涉及血管生成或增强血管渗透性的疾病的治疗剂。其中，环“A”是苯环或芳香性五元或六元杂环，可以与环状烷基环融合，“B”是烷基，R1和R2，相同或不同，是H、OH、取代或未取代的烷氧基等，X和Y，相同或不同，分别是选择自H、卤素、OH、取代或未取代的烷氧基等的基团，p为0、1或2，q为0或1。
• Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
  申请人：Honda Takahiro

  公开号：US20070149574A1

  公开（公告）日：2007-06-28

  A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R 1 and R 2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R 3 and R 4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R 5 , etc.; R 5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR 6 —, —SO 2 —, etc.; R 6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.

  一种具有4-吡啶基烷基硫基团的新型环状化合物，其中引入了（未）取代氨基或其盐。它们可用作药物。环状化合物是由以下式（1）表示的化合物，可用于治疗参与血管生成的疾病。在下式（1）中，环A表示苯环或5-或6-成员芳香杂环，可选择地与环烷环融合；B表示烷基；R1和R2各表示H，（取代）芳基，（取代）杂环基等；R3和R4各表示H，（取代）烷基，（取代）环烷基，-Z-R5等；R5表示（取代）烷基，（取代）芳基，（取代）杂环基等；X和Y各表示H等；Z表示-CO-，-COO-，-CONR6-，-SO2-等；R6表示H等；p为0、1或2；q为0或1。
• Compounds having a 4-pyridylalkylthio group as a substituent
  申请人：Honda Takahiro

  公开号：US20090286786A1

  公开（公告）日：2009-11-19

  A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: wherein A is benzene or an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R 1 and R 2 are hydrogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R 1 and R 2 join together to form a heterocycle; X and Y are hydrogen, halogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, mercapto, alkylthio, arylthio, carboxyl, an ester of carboxyl, an amide of carboxyl, cyano or nitro; p is 0, 1 or 2; and q is 0 or 1. The compound is useful for treating diseases in which angiogenesis or augmentation of vascular permeability is involved.

  一种具有以下式[I]或其药学上可接受的盐的化合物：其中，A是苯或一种芳香五元杂环，该芳香五元杂环可以选择性地与环烷环融合；B是一种烷基；R1和R2是氢、羟基、烷氧基、芳基氧基、烷基、环烷基、芳基、杂环、氨基、烷基氨基、芳基氨基或酰基，或R1和R2结合形成一个杂环；X和Y是氢、卤素、羟基、烷氧基、芳基氧基、烷基、环烷基、芳基、巯基、烷硫基、芳硫基、羧基、羧酸酯、羧酰胺、氰基或硝基；p为0、1或2；q为0或1。该化合物用于治疗与血管生成或血管通透性增加有关的疾病。
• COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT
  申请人：Honda Takahiro

  公开号：US20120202817A1

  公开（公告）日：2012-08-09

  A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: wherein A is an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R 1 and R 2 are hydrogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R 1 and R 2 join together to form a heterocycle; X and Y are hydrogen, halogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, mercapto, alkylthio, arylthio, carboxyl, an ester of carboxyl, an amide of carboxyl, cyano or nitro; p is 0, 1 or 2; and q is 0 or 1. The compound is useful for treating diseases in which angiogenesis or augmentation of vascular permeability is involved.

  以下化合物式[I]或其药学上可接受的盐：其中A是一种芳香五元杂环，可选择与环烷基融合；B是一种烷基；R1和R2是氢、羟基、烷氧基、芳氧基、烷基、环烷基、芳基、杂环、氨基、烷基氨基、芳基氨基或酰基，或R1和R2结合形成一个杂环；X和Y是氢、卤素、羟基、烷氧基、芳氧基、烷基、环烷基、芳基、巯基、烷硫基、芳硫基、羧基、羧酸酯、羧酰胺、氰基或硝基；p为0、1或2；q为0或1。该化合物可用于治疗涉及血管生成或增强血管通透性的疾病。
• NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1602647B1

  公开（公告）日：2013-10-16